TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 11C Topotecan PET Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ovarian cancer, small cell lung cancer, or other cancers~  * Metastatic brain disease~* Eligible for topotecan therapy~* Measurable disease by CT scan and/or MRI~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2~Life expectancy~* More than 3 months~Hematopoietic~* WBC ≥ 3,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Not specified~Renal~* Creatinine clearance ≥ 50 mL/min~Other~* Not pregnant or nursing~* Adequate end-organ function~* Able to tolerate lying on a radiology table for ≥ 1 hour~* No serious medical or psychiatric illness that would preclude study compliance or giving informed consent~PRIOR CONCURRENT THERAPY: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. One or more episodes recurrent CDI (defined as \> 3 loose/watery stools/24h for 2 consecutive days with CDI treatment, and not explained by another diagnosis plus laboratory confirmation of C. difficile; or ileus, or toxic megacolon plus laboratory confirmation of C. difficile, occurring within 90 days of a prior CDI episode with similar symptoms and laboratory confirmation)~2. Resolution or improvement of symptoms from most recent CDI episode, defined as no longer meeting the clinical definition for CDI for a 48 hour period during treatment, including not meeting the definition again after an initial improvement~3. Within the enrollment window: 2 days after completion of antimicrobial therapy for CDI (to allow for a washout period) to 14 days after completion of therapy or 30 days after the onset of CDI whichever is later.~4. Age 18 years~5. Enrolled in a Veterans Health Administration (VHA) facility~6. Able and willing to provide informed consent~Exclusion Criteria:~1. Unlikely to swallow capsules~2. Pregnancy, planning to be pregnant, or breastfeeding~3. Receipt of cytotoxic chemotherapy, intravenous or subcutaneous immune globulin, or confirmed neutropenia (absolute neutrophil count of \< 1,000 cells/ L) within the past 3 months~4. Inflammatory bowel disease or other chronic diarrheal disease/fecal incontinence predating CDI~5. Ongoing antibiotic use other than those for the current episode of CDI~6. Prior FMT~7. Life expectancy of \< 8 weeks~8. Anaphylactic food allergy~9. Active enrollment in another research study on antibiotics, probiotics, or FMT without investigators approval~10. Presence of an ileostomy or colostomy~11. HIV with Clusters of Differentiation 4 (CD4) cell count \< 200 cells/µL in prior 3 months~12. Decompensated cirrhosis~13. Bone marrow/peripheral blood stem cell transplant in the past year~14. Unlikely to follow study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Fecal Microbiota Therapy (FMT)
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Metabolomic Alterations in the Vascular Compartment in Patients With Sepsis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 year or older~* Sepsis or Septic shock~Exclusion Criteria:~* Pregnant or breastfeeding~* Hemoglobin ≤ 5.0 mmol/L~* Platelets ≤ 5.0 mia/L~* Consent not obtainable~* Do not resuscitate order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan (RA101495) PNH study~* Evidence of ongoing clinical benefit in the opinion of the Investigator~Exclusion criteria:~* History of meningococcal disease~* Current systemic infection or suspicion of active bacterial infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zilucoplan (RA101495) (Type: EXPERIMENTAL): Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Bandage Contact Lens Application for the Management of Corneal Abrasion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Superficial Corneal Abrasion~Exclusion Criteria:~* Incarceration~* Pregnancy~* Inability to Provide Informed Consent~* Infectious keratitis~* Retained foreign bodies in the eye~* Active infection involving the orbit or periorbital region~* Patients who are not able to or who are deemed unlikely to follow-up with ophthalmology~* A history or recent contact lens wear~* A lack of trauma or an unclear history of trauma as the inciting cause of the abrasion~* Allergy to the antimicrobial solution (POLYTRIM)~* Women who are currently breastfeeding~* Chronic eye drop use~* A history of eye surgery other than cataract surgery (greater than 6 months prior to abrasion)~* Diabetes (Patients with even mild diabetic neuropathy can have decreased pain sensation and also delayed corneal epithelial healing)~* Any eye condition that may be deemed to interfere with the conduct of the protocol or outcome measurement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bandage Contact Lens (BCL) group (Type: EXPERIMENTAL): Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have a bandage contact lens soaked in antibiotic solution placed in the affected eye
- Usual Care Group (Type: NO_INTERVENTION): Subjects diagnosed with superficial corneal abrasion in the Emergency Department will have usual care provided in the Emergency Department

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Standard CRT-D indication according to clinical routine~* De novo implantation or upgrade from existing ICD or pacemaker implant utilizing a BIOTRONIK CRT-D system with IS4 LV port and Sentus QP LV lead~* Patient is able to understand the nature of the clinical investigation and provide written informed consent~* Patient is able and willing to complete all routine study visits at the investigational site through 5 years of follow-up~* Patient accepts Home Monitoring® concept~* Age ≥ 18 years~Exclusion Criteria:~* Chronic atrial fibrillation~* Contraindication to CRT-D therapy~* Currently implanted with an endocardial or epicardial left ventricular lead or had prior attempt to place a left ventricular lead~* Cardiac surgical procedure, such as coronary artery bypass graft or valve surgery that is planned to occur within 6 months after implant or ablation that is planned to occur within 90 days after implant (ablations planned to occur prior to or at implant are not exclusionary)~* Expected to receive a heart transplant or ventricular assist device within 6 months~* Life expectancy less than 12 months~* Participation in any other investigational cardiac clinical investigation during the course of the study~* Presence of another life-threatening, underlying illness separate from their cardiac disorder~* Pregnant or breast-feeding at time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sentus QP left ventricular lead (Type: OTHER): Subjects consented and implanted with a Sentus QP left ventricular lead.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status ≤ 2 (according to WHO criteria)~* Patient with early invasive breast cancer histologically confirmed stage I to IIIA)~* Positive or negative lymph node involvement~* Positive or negative Hormonal Receptors (Estrogens and/or Progesterone),~* Equivocal HER2 status (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤ HER2 gene number copy \< 6) as assessed on surgical specimen~* Adequate Hematological, Hepatic, Renal and Cardiac Functions~* Patient potentially eligible for an anti-HER2 therapy~* Patient eligible to receive an adjuvant therapy~* Signed Informed Consent~* Patient with social insurance.~Exclusion Criteria:~* Non-measurable tumor~* Unknown Hormonal Receptors~* Unknown node involvement~* Positive or negative HER2 status (Score 0, 1 or 3 IHC, or Negative or positive ISH)~* Disease stage ≥IIIB~* Patient not able to follow the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Use of PAM 50 test in Her2 equivocal breast cancer patient (Type: EXPERIMENTAL): Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: PTNS vs Botox of Refractory OAB

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Women with refractory OAB (dry or wet)~2. OAB will be defined by a positive response and bother of somewhat, quite a bit, a great deal, or a very great deal to question #3 or #8 on the OAB-q (see appendix B) regarding urinary urgency and urgency incontinence.~3. Refractory will be defined as failure of 2 prior treatments, including behavioral modification, pelvic floor physical therapy, and OAB medication (anticholinergics or mirabegron). Trial of 2 medications that did not improve symptoms after 2 weeks or could not be tolerated due to side effects will constitute 2 treatment failures.~4. Women with mixed urinary incontinence that is urge predominant will also be included.~5. Age ≥ 18 years~6. English speaking~7. Available for 1 year follow-up~8. Able to complete study questionnaires~Exclusion Criteria:~1. Neurologic disease known to cause OAB including, but not limited to, Multiple sclerosis, Parkinson's disease, and Spinal Cord Injury.~2. Pregnancy by self-report or pregnancy test~3. Contraindication to PTNS and/or BTX~   * PTNS: Pacemaker~  * BTX: myasthenia gravis, allergy to BTX, urinary retention (post void residual \>200cc)~4. Planned surgery for pelvic floor disorder during the study period~5. Prior treatment with BTX, PTNS, or sacral nerve stimulation (SNS) for refractory OAB/urinary urge incontinence (UUI)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnabotulinumtoxinA (BoNTA) (Type: None): DRUG: OnabotulinumtoxinA (BoNTA) is an injection into the bladder which blocks the presynaptic release of acetylcholine. BoNTA was approved for the treatment of OAB by the FDA in 2013.
- Percutaneous tibial nerve stimulation (PTNS) (Type: None): DEVICE: PTNS involves needle stimulation of the posterior tibial nerve and is typically performed with weekly 30 minute sessions for a 12 week treatment course.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic patients: defined as fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate \>22 per minute).~2. Nasopharyngeal RT-PCR positive SARS-CoV-2~3. Age 20-50 years~4. BMI 18-28 kg/m2~5. Informed consent~Exclusion Criteria:~1. O2 saturation by pulse-oximeter below 93%~2. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes~3. Arrhythmias and/or history of arrythmia~4. Psoriasis and/or history of psoriasis~5. Neuropathy or myopathy and/or history of these~6. Hypoglycemia and/or history of hypoglycemia~7. Pre-existing hepatic disease~8. Pre-existing renal disease~9. Use of antacids within 1 week~10. Use of antiobiotics within 1 week~11. Pregnancy~12. RT-PCR performed \>7 days prior to enrollment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- HCQ Regular dose (Type: ACTIVE_COMPARATOR): Hydroxychloroquine loading dose (400 mg BID for 2 days) followed by 200 mg BID for 4 days plus standard of care
- HCQ Loading dose (Type: EXPERIMENTAL): Hydroxychloroquine loading dose (400 mg BID) alone plus standard of care
- CQ regular dose (Type: ACTIVE_COMPARATOR): Cholorquine 500 mg BID for 5 days plus standard of care
- Placebo (Type: PLACEBO_COMPARATOR): Standard of care plus placebo (cannot be treated with hydroxychloroquine or chloroquine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Injection for DeQuervain's

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pain with palpation at 1st dorsal compartment at wrist and positive Finkelstein's Test~Exclusion Criteria:~* Patients with evidence of osteoarthritis or degeneration of the wrist.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Unguided injections (Type: ACTIVE_COMPARATOR): Corticosteroid injection (betamethasone) without ultrasound guidance.
- Ultrasound-guided injections (Type: ACTIVE_COMPARATOR): Corticosteroid injections (betamethasone) under ultrasound guidance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interleukine 6 (IL6) Assay for Predicting Failure of Spontaneous Breathing in Patients With COVID-19 Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18 years~* Patients with COVID-19 (positive COVID PCR)~* Use of intubation for mechanical ventilation~Exclusion Criteria:~* Use of Extracorporeal Membrane Oxygenation~* Treatment with Tocilizumab (anti-Il6)~* Pregnant woman~* Patients under protective administration or deprived of liberty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with COVID-19 acute respiratory distress syndrome (Type: OTHER): Patients with acute respiratory distress syndrome due to COVID-19 and requiring mechanical ventilation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Excision Limits of Oral Cavity Tumor by Narrow Band Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primitive epidermoid cancer of the oral cavity, proved by histology, not treated previously, patient having a surgery~* No previous surgery for this cancer~* Age \> 18 years~* Patient affiliated to health insurance~* Consent signed by the patient~Exclusion Criteria:~* Metastatic or recurrent disease~* Health care impossibilities for geographic, social, psychic reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient with oral cavity cancer (Type: EXPERIMENTAL): Patient treated by surgery for the oral cavity cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Minimally Invasive Versus Conventional Approaches in Navigated Total Knee Arthroplasty (TKA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indication for elective TKA~* agreement to participate in this study~Exclusion Criteria:~* Body Mass Index (BMI)\>40kg/m²~* varus or valgus deformity \>20°~* Range of Motion (ROM) \<75° flexion/extension~* concomitant diseases like: rheumatoid arthritis osteoporosis intake of cortisone diabetes former operations on the concerned knee~* infections in the operated joint during the follow-up period~* Thromboses during the follow-up period

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Navigated total knee arthroplasty with a minimally invasive approach
- 2 (Type: ACTIVE_COMPARATOR): Navigated total knee arthroplasty with a conventional approach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type II diabetes regardless of duration of diagnosis with an admission blood glucose level between 140 mg/dL to 400 mg/dL will be included in the study.~* Other inclusion criteria are as follows:~  * age 18-80 years old~ * treated with diet alone~ * any combination of oral anti-diabetic agents or insulin treatment with any dosage before admission.~Exclusion Criteria:~* Hyperglycemia without a known history of diabetes~* H/o recent cardiac surgery (within 6 months)~* Impaired renal function (glomerular filtration rate less than 45)~* History of diabetic ketoacidosis~* Diabetes mellitus type 1~* Pregnancy~* Patients on steroid treatment~* Known hypopituitarism or adrenal insufficiency~* Known hypoglycemia of unawareness~* Length of stay \<48 h~* And severe liver disease and patent admitted in intensive care unit.~* Patients already received an insulin dose greater than 0.5 units/kg body weight after admission prior to initiation of study protocol will be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NPH and regular insuline group (Type: EXPERIMENTAL): For the group receiving NPH and regular 2/3 and 1/3 formula will be followed. If Nil per os (NPO), patient will receive NPH twice daily but AM dose will equal to PM dose. Regular insulin given along with NPH will be held while patient is NPO. A correctional dose of regular insulin will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they could also receive correctional doses of regular insulin. Correctional insulin could be given four times daily with meals or at bedtime.
- glargine and humalog group (Type: ACTIVE_COMPARATOR): Half of the total insulin dose will be given as glargine once daily, either in the AM or in the PM, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as humalog; doses were divided equally between breakfast, lunch, and dinner. An additional correctional dose of humalog will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they received glargine once daily and could also receive correctional doses of humalog. Correctional humalog could be given four times daily with meals or at bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues